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ABSTRACT

Compositions containing as the active ingredient a spin

trapping reagent, preferably ot-phenyl butyl nitrone (PBN)
or spin-trapping derivatives thereof, in a suitable pharma
ceutical carrier for administration to a patient are disclosed

for treating or preventing symptoms associated with aging or
other conditions associated with oxidative tissue damage.
Other spin-trapping agents can also be used, such as 5,5

dimethyl pyrroline N-oxide (DMPO) or 0t-(4-pyridyl l-ox

ide)-N-tert-butylnitrone (POBN), and other spin-trapping
derivatives thereof. These compositions and methods are

useful in the treatment of age-related disorders, pre-surgical
and/or pre-anesthetic preparation or administration of che
motherapeutic agents, and in the treatment of disorders or

trauma of the brain, cardiovascular system, and lymphatic
system. Studies in animals demonstrate that administration
of compound for a two week period reduces the level of
oxidized brain enzymes to normal and restores memory to
the same level as tested in young control animals.
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5,578,617
Page 2
OTHER PUBLICATIONS

Smith et al., Gastroenterology, 92, 950-956 (1987).
Chen et 21., Free Rad. Res. Comms. 9(3-6) 317-323 (1990).
Bolli et 211., Free Rad. Res. Cornms. 9(3-6) 169-180 (1990).

Rau et 211., Free Rad. Res. Comms, 9(3-6) 197-204 (1990).
Reinke et 211., Free Rad. Res. Comms, 9(3-6) 205-211

(1990).
Janzen et a1. Free Rad. Res. Comms. 9(3-6) 353-360

(1990).

Carney et al., J. Mol. Neurosci (1990) 3:47-57.

Floyd et al., Arch. Geront. Geriatn, 12 (1991) 155-177.
Carney et al., Proc. Natl. Acad. Sci. USA, Vol. 88, pp.
3633-3636 1991.
Oliver et 211., Proc. Natl. Acad. Sci. USA, vol. 87, pp.

5144-5147, 1990.
Kindy et al., J. Mol. Neurosci, 2:217-228 (1991).

US. Patent

Nov. 26, 1996

Sheet 1 of 5

5,578,617

FIG.
_

w
257
50O

V/ / vV/ /%

young gerbil

V/ /%

A

control

(3-4 months) old gerbil
control

(12-15 months)
old gerbil
(12-15 months)
+ 0.1 ml saline

bid.

old gerbil

(12-15 months)

+ 10 mg PBN/kg
b.i.d.

50m
_
_
_

US. Patent

@E2$4598061%5

14

.20864

Nov. 26, 1996

Sheet 2 of 5

5,578,617

OLD GERBIL

YOUNG GERBIL

_ / / / / / / 7/ /, / /, /A 7/ / 7/ , / /, 7/ /
C

1 3 7 14
DAYS OF PBN

C

1 3 7 14
DAYS OF PBN

32 mg PBN/kg bodyweight b.i.d.

FIG. 2A
OLD GERBIL

YOUNG GERBIL

_
_

321

7/ / 7/ , 7/? A 7/ / / 7/ /% 7/ / 7/
/A

C13 714
DAYSOFPBN

C

13 714
DAYS OF PBN

FI G. 213
32 mg PBN/kg bodyweight b.i.d.

US. Patent

Nov. 26, 1996

FIGBA

Sheet 3 0f 5

5,578,617

1. 2

5R28m60@E2\_0oE3&

396

_

a a’

0

01

7
DAYS POST PBN

14

Administered to old gerbils (10 mg PBN/kg b.i.d.)

FIG.

lllllllllillill
14
7
O1

0

Administered to old
DAYSgerbils
POST(10
PBNmg PBN/kg b.i.d.)

FE

O

£08852 12@5U68C20

_
_
_

m
n
m
wo

g

7/,7/ /

_

_

Z

llllllllllllll

14

O1

DAYS POST PBN

Administered to old gerbils (10 mg PBN/kg b.i.d.)

U.S. Patent

Nov. 26, 1996

Sheet 4 of 5

5,578,617

F1 G. 4A

ACMAUuOLQM1

FIG. 4B

_
_
T1|l . (/\

“MoEH7/r/a37/ I
n
.M.
u
H
m
H
_
g

wWEII.wi_mlI/ l!mI

t.re1..*0
r.o
l.lI
m
_
_
Hm
_
_
_
_

5@828do5c_08926m0

Im
,D
M
D

m
m
_
_
III ,

mgI
%I_VMI71I I

m
_
u
w
n
w
Iw
I
m
m
_
_
III

II.Nl

M9W.EImgil/Afr

“
n
m
H
.I.
H
m

“M
W
%
H
w
IQ
0O31296

F I. G. 4. C
_
_
_
_

O1
DAYS POST PBN

Administered to old gerbils (32 mg PBN/kg b.i.d.)

5,578,617

US. Patent

FIG.

42m~3o<m52

O4286

_
_

IV/ /% T7/ % _|%/ /%

old gerbil

l

(12-15 months)
saline

o

(1 2 10

"19/

h )
b d

old gerbil

(12-15 months)

32 mg/kg PBN b.i.d.

young gerbii

(3—4 months)
saline

5,578,617
1

2

METHOD AND COMPOSITIONS FOR
TREATING AGE RELATED DISORDERS

investigators, there are no reports of substantial investiga
tions in which alterations in the oxidized protein burden of
the central nervous system was manipulated and correlated

This is a divisional of application Ser. No. 08/027,559
?led on Mar. 5, 1993, now US. Pat. No. 5,405,874, which
is a CONT of Ser. No. 07/589,177, ?led Sep. 27, 1990 now

with a functional outcome on the part of the animal. Such an

approach, if truly associated with brain dysfunction, would
provide a basis for reversing the age related neuronal de?cit
of cells that are still viable. Thus, such an approach is
targeted at cells which are marginally functional but still
viable.

abandoned, which is a CIP of Ser. No. 07/422,651, ?led Oct.
17, 1989, now US. Pat. No. 5,025,032.
BACKGROUND OF THE INVENTION

It is therefore the object of the present invention to

provide composition and methods for the use in preventing
or reversing age related functional de?cits.
It is further the object of the present invention to provide

The present invention is a’ method and compositions
containing spin trapping agents for the treatment of age

related dysfunctions and other conditions arising from oxi
dative damage.

15

composition and methods for use thereof which are useful in

preventing and reversing cognitive de?cits associated with

Age related changes in central nervous system function
have generally been associated with the loss of cells, a
widening of lateral ventricles and de?cits in short term
memory. The precise mechanisms of functional changes as
a result of aging, or other diseases associated with aging,
have not generally been agreed upon.
Several mechanisms for the generation of oxidized mate
rial in the brain have been proposed. In particular, transition
metals, especially iron and copper, have been suggested as
mediating aspects of this oxidation. A marked reduction in
certain neurotransmitter receptor systems has been associ
ated with increased oxidation of proteins. For example,
decreases in muscarinic receptors and other cholinergic
systems have been characterized as they relate to alterations
in functions in Alzheimers disease. It has also been hypoth

preventing symptoms associated with aging or other condi
tions associated with oxidative tissue damage. The preferred

esized that aging is associated with multiple minor periods

PBN compositions have the following general formula:

infection or in?ammation.

It is another object of the present invention to provide

composition and methods reducing post traumatic cognitive

dysfunction.
SUMMARY OF THE INVENTION

Compositions containing as the active ingredient a spin

trapping reagent, preferably ot-phenyl butyl nitrone (PBN),
or spin-trapping derivatives thereof, in a suitable pharma
ceutical carrier for patient, are disclosed for treating or

of ischemia (multi-infarct conditions or transient ischemia
attacks) which, over a period of time, may give rise to the

production of oxidized protein.
Changes associated with ischernic brain disease have been
proposed to be the result of alterations in calcium disposi

H

O

X

Y

35

tion, increase in excitoxic neurotransmitter release, produc

wherein:
X is phenyl or

tion of free radicals and the attendant acidosis that results in
an increase in the loosely related metals in the cell that are
catalytic for the generation of oxygen free radicals. These
changes are largely limited to neuronal elements. Reactive

(OR)n

glia have been demonstrated, however, they are mostly
associated with postneuronal damage.

'

The treatment of age related dementias have been largely

45

limited by the inability to develop an appropriate model for
the study of this condition. This is due to the fact that aging

wherein R is H,

is a very complicated condition which is di?icult to model,

especially with the lack of speci?c information associated
with the functional and biochemical basis of human age
related dementias. The use of animal models has largely

Y

depended upon model systems used in brain studies, where
the brains are not truly senescent, or the use of senescent

and n is a whole integer from 1 to 5; or

animals, with little understanding of the origin of the senes
cence or, in some cases, the inability to demonstrate truly 55
functional senescence.

The demonstration in a variety of systems, both neural
and nonneural, that there is an age related enhancement of
the level of oxidized protein in tissue gives rise to the
possibility that age related dysfunctions in the .central ner 60
vous system may be associated with the build-up of oxidized
proteins and oxidized macromolecules within neurons

OW

throughout the central nervous system. The hypothesis is
that cells which have a buildup of oxidized protein are less
functional and less able to maintain the speci?ed role of
those cells in that particular area of the central nervous

system. While this hypothesis has been suggested by several

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

65
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of twice daily injections of PBN. FIG. 3C demonstrates the
time related decrease in alkaline protease activity following
termination of twice daily injections of PBN. Each histo

wherein W is

gram is the mean i standard error (S.E.) of three subjects at
each of the indicated times. The asterisk and dashed line

indicates the old gerbil, untreated control values for each of
the measures.

FIGS. 4A, 4B and 4C are graphs comparing changes in
or Z; and

10

protein carbonyl (pnol/mg protein) (FIG. 4A), glutamine
synthetase (FIG. 4B), and protease activity (% control)

Z is a C1 to C5 straight or branched alkyl group.
Other spin-trapping agents can also be used, such as

(FIG. 4C) over days following termination of twice daily
dosing with 32 mg PBN/kg body weight. FIG. 4A represents

5,5-dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl
l-oxide)-N-tert-butylnitrone (POBN), and other spin-trap
ping derivatives thereof.

the level of carbonyl in the soluble protein obtained from
gerbils treated for fourteen days and tested at l, 3, 7 and 14
days post dosing. FIG. 4B is the time related decrease in

In the preferred embodiment, the compositions are admin~

cortical glutamine synthetase (GS) activity after termination

istered one to two times daily by oral administration, at a

of twice daily injections of PBN. FIG. 4C demonstrates the
time related decrease in alkaline protease activity following
termination of twice daily injections of PBN. Each histo

dosage equivalent to between one and ten milligrams PBN/

70 kg of human body weight. Studies in animals demon

gram is the mean i SE. of three subjects at each of the
indicated times. The asterisk and dashed line indicates the
old gerbil, untreated control values for each of the measures.
FIG. 5 is a graph of the eight arm radial arm maze
performance of young or old gerbils treated with either

strate that administration of compound for a two week

period reduces the level of oxidized brain enzymes to
normal and restores memory to the same level as tested in

young control animals. A signi?cant reduction in oxidized
proteins and memory recovery is observed as early as seven

days after initiation of treatment; levels are still comparable
saline or PBN. Gerbils were placed into the central com
to young controls one to three days following cessation of 25 partment of the maze with the barrier in place to limit
treatment, and partially reduced at seven days following
exploration. After the barrier was removed, the number of
cessation of treatment.
arms re-entered and the total elapsed time before all eight
These compositions and methods are useful in the treat
arms were entered was recorded. Each histogram represents
ment of age-related disorders, pre-surgical and/or pre-anes
the mean i of 18 gerbils. The animals were administered

thetic preparation or administration of chemotherapeutic

PBN twice daily (either 10 or 32 mg PBN/kg body weight)

agents, and in treatment of disorders or trauma of the brain,

for seven days and tested at the end of seven days of dosing.

cardiovascular system, lymphatic system, and, potentially,
in the treatment of some viral disorders characterized by

DETAILED DESCRIPTION OF THE
INVENTION

oxidation of host proteins in cells infected by the virus.
BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a graph of the alkaline protease activity from
gerbil cortex (% of young, three to four month old gerbil
cortex) for young gerbils (age three to four months), old
gerbils (retired breeders of twelve to ?fteen months of age),
old gerbils that received twice daily injections of 0.1 ml

35

40

It has now been discovered that, further to the methods
using PBN for the treatment and prevention of ischemic
damage described and claimed in US. Ser. No. 07/422,651
?led Oct. 17, 1989, spin-trapping agents are useful in

preventing or treating symptoms associated with aging,
trauma, drug administration and surgery, especially of the

saline/kg body weight, and old gerbils that received twice
daily injections of 10 mg PBN in saline/kg body weight for

brain. As used herein, a free radical scavenger or spin-trap
reagent is a molecule that will form a stable complex with
free radical. A free radical carbon trap is a molecule in which

two weeks. Protease activity was determined using oxidized

the free radical is localized on a carbon atom or a nitrogen

protein extracted from young gerbil cerebral cortex.
FIG. 2A and FIG. 2B are graphs comparing protein

radical is no longer damaging to the cell. In combination

carbonyl activity (pmol/mg protein) (FIG. 2A) and

with a pharmaceutical vehicle suitable for administration to

glutamine synthetase activity (FIG. 2B) in the cerebral

a patient, preferably by oral administration, these com
pounds are useful in preventing or reversing symptoms
associated with aging, for example, increased levels of

cortex (neocortex) of young adult and old gerbils over days
of administration of 32 mg PBN/kg administered twice a day
for one, three, seven or fourteen days. At the end of each of

the days indicated, animals were decapitated and cerebral
cortex removed and rapidly frozen in liquid nitrogen. Pro
tein carbonyl content was determined using the DNPH
procedure. The results demonstrate the reduction in oxida
tive damage to proteins and the loss of enzyme activity in

atom. As a result of this chemical bond formation, the free

50

oxidized proteins, decreased enzymatic activity, and spatial

and short term memory. Currently, there are no effective,
non-toxic treatments for aging. Effectiveness has been dem
onstrated in animals after as few as seven days of adminis
tration. Effectiveness continues for at least one week after
55
administration. Values return to pre-treatmerrt levels after

gerbil cerebral cortex as a result of twice daily administra

two weeks.

tion of 32 mg PBN/kg (i.p.). Each histogram is the mean of

three subjects.

Useful Spin-trapping Compounds

FIGS. 3A, 3B and 3C are graphs comparing changes in

PBN and Derivatives thereof

protein carbonyl (pnol/mg protein) (FIG. 3A), glutamine

The preferred spin-trapping compounds are ot-phenyl

synthetase (FIG. 3B), and protease activity (% control)
(FIG. 3C) over days following termination of twice daily
dosing with 10 mg PBN/kg body weight. FIG. 3A represents
the level of carbonyl in the soluble protein obtained from
gerbils treated for fourteen days and tested at 1, 3, 7 and 14
days post dosing. FIG. 3B is the time related decrease in
cortical glutamine synthetase (GS) activity after termination

t~butyl nitrone (PBN), and derivatives thereof. PBN has no
measurable effect on normal or uninjured cells. PBN is the

preferred compound at this time, although a number of
65

derivatives are also useful, including hydroxy derivatives,
especially 2-, 3- or 4-hydroxy PBN and mono-, di- and

trihydroxy tert-butyl nitrone; esters, especially esters which

5,578,617
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release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such as the

Other Spin-trapping Reagents

acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl

Other spin-trapping agents can also be used, such as

nitrone, such as the ethyl derivative, or phenyl hydroxybutyl
nitrone, such as the acetoxy derivative; alkoxyl derivatives,
especially alkoxyl derivatives which release 2-, or 4-hydrox
yphenyl t-butyl nitrone, such as the methyl derivative; and
acetamide derivatives, especially acetamide derivatives

5,5-dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl

l-oxide)-N-tert-buty1nitrone (POBN), and spin-trapping
derivatives thereof. Derivatives are made using standard

techniques, for example, for substitution of the methyl
groups. The general formula for DMPO is:

which release 2-, or 4 aminophenyl t-butyl nitrone, such as

the acetyl derivative; diphenyl nitrone (PPN) and the analo
gous diphenyl nitrone derivatives. As used herein, “PBN”
refers to both phenyl t-butyl nitrone and derivatives thereof,
unless otherwise stated.
The general formula for PBN and useful derivatives

A 7@
B

N

4

thereof is:

wherein A and B are independendy CH3, CHZOH, CHZOW,
X

/

\Y

20

wherein:
X is phenyl or
25

(OR)n

n is an integer from 1 to 5

wherein W is
30

wherein R is H,

Y

35

or Z; and

and n is a whole integer from 1 to 5; or

Z is a C1 to C5 straight or branched alkyl group.
The general formula for POBN is:
40

l
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or
OW
N

0

wherein W is
55

wherein
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

o

0

ll

ll

/OW

c-crn, 0-02,
60

or Z; and

Z is a C1 C5 straight or branched alkyl group.

5,578,617
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particular brain region could result in acquisition de?cits,

wherein W is -—C—CH3,

whereas oxidation of a di?erent region could result in output

de?ciency. Considering the number of devastating neurode

generative diseases, including Alzheimer’s disease, this
treatment could potentially be a tremendous help to people
with these disorders.
Examples of other disorders that can be treated with these

or Z; and

S is H, (OR),,, wherein R is H,

compositions include peripheral neuropathy of diabetes,
exercise induced muscle damage and pain, and enhancement
of cellular response to hormonal signals.

Treatment of Neurodegenerative Disorders
Several neurodegenerative conditions are most appropri
wherein Y is as de?ned above,

15

ately treated by compounds that interfere with protein oxi
dation. Alzheimer’s disease has been associated with the

n is a whole number from 1 to 4, or

accumulation of abnormal oxidized proteins or the produc
tion of abnormal proteins in areas that are pathologically
affected. In addition, age related enhancement in protein
oxidation occurs in all cells in the aged individual. PBN and
derivatives thereof have been demonstrated to be useful in

Z is a C1 to C5 straight or branched alkyl group.
Indications that the Compositions are Useful in

25

Treating

the reduction in protein oxidation and in the increase in the
activity of critical enzymes within the brain of aged animals.
Since this is a fundamental change in oxidative state, it is
likely that PBN and other related compounds would be
useful when given chronically to individuals who are in the

early phases, or possibly in the late phases, of Alzheimer’s
disease. In addition, multi-infarct dementias should be treat
able With these compounds, since they also deal with

The free-radical scavenger compositions are useful in
treating a variety of dysfunctions or disorders characterized
by oxidized proteins in the tissues or cells. Oxidation of

ischemia reperfusion oxidation issues.
Senile dementia has not been directly evaluated for

cytosolic protein has been demonstrated to occur in a wide

variety of pathological conditions. Accordingly, compounds

ischemia reperfusion etiology or protein oxidation, however,

which have as their fundamental mechanism of action the
interference of production of oxidized protein should be
useful in the treatment of a wide variety of diseases having
what appears at ?rst glance to be widely dissimilarretiolo
gies, because the fundamental cause of the condition is
oxidation of protein or nucleic acids.
In one embodiment, the spin-trapping agent is adminis

it is likely that senile dementia would also be treatable with
these compounds. This is based on the hypothesis that
advanced age is associated with increased production of
oxidized protein. In progeria, a unique condition in which
aging is accelerated, Stadtman and colleagues at the NIH

tered to a patient to reverse the damage occurring as a

35

40

have demonstrated that there is a marked increase in the
base-level of oxidized protein even in young adult subjects
with progeria, as reported by Oliver, et al., J. Biol. Chem.

45

Biochem. Biophys. 275, 559-567 (1989). While this is a rare
condition it should also be treatable with these composi
tions.
Another condition which is likely to be associated with

262, 5488—5491 (1987) and Starke-Reed and Oliver, Arch.

function of age. Preliminary results indicate that there is a
net increase in the oxidation of proteins and the accumula
tion of oxidized material in the brain. The development of

senil plaque is also routinely observed in aged patients.
Other disorders are those resulting from trauma, such as
a blow to the head, or from drug treatment, for example,

oxidative damage arising from microcirculatory di?iculties
is the diabetic peripheral neuropathies and vascular change.

administration of anesthesia or drug abuse, or even as a

These are tragic conditions in which amputation is eventu
result of some types of viral infections.
ally necessary in order to save the patient. While these
It has now been determined that the level of oxidized 50
compounds are not likely to improve vascular ?ow they are

brain protein appears to be inversely related to performance

likely to reduce the impact of transient changes in vascular
?ow which result in oxidation and damage to the peripheral

in a short term memory task and directly related to risk of

stroke-induced damage and behavioral change. Increased

nerves and also in damage to the skeletal muscle which is
often associated with the condition called exercise induced
ing: (a) oxidative damage to cellular proteins could cause a 55 or intermittent claudication. If the retinopathy associated
change in the regulation of ion channels, there could be a
with diabetes is also an ischernia reperfusion microcircula
cellular oxidation may result in one or more of the follow

change in the rate and efficiency of signal translation and
membrane depolarization, signi?cant changes in energy

tion problem, then the spin-trapping compounds will be
useful in treating the retinal damage which occurs very

?uxes may occur and compromise selective function, the
?delity of RNA transcription may be altered due to oxidative
damage to DNA, RNA translation may be aifected either by

frequently in diabetic patients.

Pre-surgical Preparation

oxidation of the RNA or regulatory macromolecules, or the

rate of protein degradation may be altered.
Any of these changes could negatively impact on the
acquisition consolidation and retrieval of information, even
by interference with a single step in the learning and
memory process. It is possible that oxidation of cells in a

Since the status of the cell and its survival in a hypoxic or

anoxic environment is dependent upon the ability of the cell
65

to compartmentalize metals and handle oxygen in a useful

manner, in contrast to peroxidation, it is expected that these
compounds will be useful as presurgical preparatory medi
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cation to reduce the carbonyl load and improve the enzyme
status of the patient prior to elective surgery. These com
pounds would also help the cells of the body achieve a

In the preferred application, the PBN is administered to a
patient suffering from memory loss or other symptoms

frequently associated with aging. Optimum results are gen
erally observed after two weeks of daily or twice daily oral
administration. The compositions can also be effectively
administered prior to, during or shortly after surgery, and
prevent or decrease the extent of cellular damage resulting

higher level of enzymatic function, shorten the recuperative
phase, and reduce the likelihood of any interoperative com

plications associated with changes in microcirculation.

from either the trauma or anesthesia.

Treatment of Viral Infections and In?ammatory
Disorders

Since the trapping of endogenous free radicals is speci?c
10

Retroviruses selectively infect certain types of cells, such
as lymphocytes. An example of a retrovirus that has been the

little or no effect on normal cells. The bene?cial effects

subject of much research activity is the human immunode
?ciency virus (HIV), which causes Acquired Immunode?
ciency Syndrome (AIDS). No means for prevention of

occur only’in injured cells, and do not require the presence

of speci?c receptors, speci?c enzymes, and/or speci?c cell
types.

infection has been found, although there have been numer
ous attempts to ?nd a treatment. Since activation of lym

Methods of Administration of PBN

phocytes is associated with the oxidation of protein and
activation of lymphocytes is required prior to release of
newly formed viruses, it is expected that administration of
these compositions will inhibit infection and replication of
lymphocytes by the viruses. The activation of the T-4
lymphocyte is associated with a cascade of biochemical
intracellular changes, one of which is the production of
oxidized protein. If PBN related compounds can block
protein oxidation in the abnormal process then it is possible
that PBN or other spin-trappin compounds could in fact
interfere with the process of viral replication and/or dissemi
nation of the virus from the host cell (T-4 lymphocyte),
thereby acting as a virustatic agent by preventing the T-4

for only those cells that have been exposed to the conditions
that result in the production of free radicals, the traps have

The PBN is preferably administered systemically, most
preferably orally, since this is the most rapid and efficient
means for'delivering the active compound to the site of free
radical generation. The PBN may be administered at once,
or may be divided into a number of smaller doses to be
25

administered at varying intervals of time. Other methods of
administration can also be used, including subcutaneous,
intravenous, and intraperitoneal administration. The concen

tration of active compound in the drug composition will
depend on absorption, inactivation, and excretion rates of
30

lymphocyte from releasing the newly formed viruses. This

the drug as well as other factors known to those skilled in the
art. The effective dosage may also be determined based on
that amount required to prevent or reverse predisposition of

the cells to damage resulting from depletion of ATP (as
demonstrated by in vivo NMR) and damage from free

would be analogous to the use of isoniazid (INH) in the
treatment of tuberculosis. At low doses INH is a tubercula

radical generation. It is to be noted that dosage values will
also vary with the condition of the patient being treated. It
is to be further understood that for any particular subject,

static in that it reduced the infectivity and spread of the

tuberculosis, thereby effectively protecting the patient from

pulmonary damage.
compounds occur in animals that have a base-level of

speci?c dosage regimens should be adjusted over time
according to the individual need and the professional judg

carbonyl formation which appears to be necessary for post
translational processes. Old animals have a signi?cantly

ment of the person administering or supervising the admin
istration of the compositions, and that the concentration

elevated level of carbonyl protein which is associated with
decreased enzymatic function relative to young control

ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed

It is important to note that the effects of the spin-trapping

composition.

animals. When young control animals are given the exact

same dosage regimen, there is no signi?cant change in
enzyme activity nor is there signi?cant change in protein
carbonyl. Thus the PBN and related spin-trapping com

A preferred mode of administration of the active com
45

pound is in a form for oral delivery. Oral compositions will
generally include an inert diluent or an edible carrier.

pounds are not likely to interfere with fundamental pro

Preferred pharmaceutical carriers for intravenous adminis

cesses that are necessary for the normal cellular function.

tration are saline or phosphate buffered saline at physiologi

cal pH. Since PBN degrades at pH less than approximately

In conclusion, a number of clinical conditions appear to
have as their fundamental cause'oxidation of cellular protein

3 to 4, it is preferred to administer the PBN at a pH of 4 or
higher, or in combination with food, a buffering agent, or in
an enteric coating. For oral delivery, the PBN may be

and enzymatic damage. Spin-trapping compounds are effec
tive in animal models in reducing the protein oxidation and
improving enzymatic function. This occurs in preparations
in which the abnormal-oxidized protein is modi?ed and
protected but the normal post translational oxidation is
allowed to occur. This would suggest that PBN does not

enclosed in capsules, compressed into tablets, microencap‘
sulated, entrapped in liposomes, in solution or suspension,
55

alone or in combination with a substrate immobilizing
material such as starch or poorly absorbable salts such as

interfere with the normal necessary oxidation of proteins

immodium. Pharmaceutically compatible binding agents

following synthesis.

can be included as part of the composition. The tablets or

Effective Dosages of PBN

capsules may contain, for example, any of the following
ingredients, or compounds of a similar nature: a binder such

as microcrystalline cellulose, gum tragacanth or gelatin; an
excipient such as starch or lactose, a disintegrating agent
such as alginic acid, Primogel®, or corn starch; a lubricant
such as magnesium stearate or Sterotes; a glidant such as
mg/70 kg body weight. Toxicity tests have demonstrated that 65 colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a ?avoring agent such as peppermint, methyl
the compound is completely innocuous, with such low
salicylate, or orange ?avoring. When the dosage unit form is
toxicity that it was not possible to determine an LDSO.

Exemplary dosages of PBN range from 0.1 to 10 mg/kg
of body weight in animals. The e?’ectivedosage of PBN in
humans is expected to be between approximately 1 and 10

5,578,617
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a capsule, it can contain, in addition to material of the above

As can be seen in the ?gure, there is no change in the level

type, a liquid carrier. In addition, dosage unit forms can

of oxidized protein of young gerbils treated for up to 14 days
with PBN. This indicates that the level of oxidized protein

contain various other materials which modify the physical
form of the dosage unit, for example, coatings of sugar,

is likely to be a natural and necessary post translational

effect, for example, if after synthesis of the protein, the
protein is activated by a modi?cation involving carbonyl

shellac, or other enteric agents.
The present invention will be further understood with

oxidation. In contrast to the carbonyl level seen in young

reference to the following non-limiting examples demon—
strating methods for determining effectiveness of PBN

animals, control aged animals (15 months of age) have a
marked increase of carbonyl content. This increased carbo
administration for treatment or prevention and/or reversal of
nyl content is responsive to treatment with PBN. Multiple
10
symptoms associated with aging.
days of treatment with PBN results in a progressive reduc
tion in the level of protein carbonyl to the level seen in
young animals.
EXAMPLE 1

The level of protein carbonyl reduction (oxidized protein

Determination of Brain Enzyme Levels in Old
Versus Young Gerbils Treated with PBN
A correlations between the duration of ischemia and either
the change in spontaneous behavior or the level of oxidized

20

brain protein has previously been demonstrated in gerbils.
Many other psychiatric and neurological conditions have
been proposed to be the result of oxidation, Among these
conditions, cellular aging has been associated with oxygen
radicals and the accumulation of proteins. The level of

sive to treatment with PBN. The ability of PBN to reduce the

protein carbonyl load of cells also indicates that this is an
25

oxidized protein, glutamine synthetase activity, brain pro
tease activity and radial arm maze performance in young

adult and retired breeder gerbils have now been compared
and demonstrate that there is a direct relationship between
the age of the subject and the level of oxidized brain protein,
as measured using a protein carbonyl assay. Increased levels
of protein carbonyl were associated with decreased

30

glutamine synthetase activity and decreased alkaline pro
tease activity. In contrast, there was no change in acid

protease activity of retired breeders, compared to young
adult gerbils. Consistent with the age-related increase in
protein oxidation and enzyme damage, retired gerbils made

burden of neurons in the brain) is only to the level of the
normal young gerbil brain. Neither the levels in the young
gerbil brain nor the levels in the senescent gerbil brain can
be further reduced beyond this level. This observation
supports the hypothesis that there is a necessary level of
oxidation that occurs in cells in normal animals, which is
required for cells to have “normal function”, and that control
aged animals (15 months of age) have a marked increase of
carbonyl content. This increased carbonyl content is respon

35

active oxidation process which occurs at a regular or pre
dictable rate and that there are mechanisms existent within
the cells of the brain which can remove this oxidized protein

if the process is interrupted.
FIG. 2B compares the levels of glutamine synthetase (gs)
in young and old animals and evaluates the effects of daily
administration of PBN on the speci?c activity of the
enzyme. This particular enzymatic marker has been selected
because it is a highly sensitive protein to oxidation and
because it is a metalloprotein that has bound to it metal
which may participate in the generation of free radicals if the
metal is dissociated with its binding site. Glutamine syn

thetase activity has been used by Stadman and colleagues

signi?cantly greater numbers of errors in a test of short-term

memory, compared to young adult gerbils. These studies
demonstrate that the functional de?cits that occur as a result 40

of aging may be associated with increased protein oxidation

(Oliver, et al., Proc. Natl. Acad. Scie. USA 87, 5144-5147
(July 1990)) as a marker enzyme for alterations following

protein oxidation.

As shown in FIG. 2B, the level of glutamine synthetase is
and decreased brain enzyme activities.
lower in old gerbils (1.2) than in young adult gerbils (2.1).
This system has been used to demonstrate the effective
This is consistent with previous studies in which increases in
ness of PBN in restoring young brain enzyme levels and
45 the level of the carbonyl protein (oxidized protein in cells)
short term memory to old animals. The results are shown in
is associated with a decrease in glutamine synthetase activ
FIGS. 1 through 5, as follows. Young gerbils were obtained
ity. In particular, if the glutamine synthetase enzyme is

from Tumblebrook Farms, West Brook?eld, Mass, weigh

ing 50-60 grams and age three to four months. Control
gerbils were given saline. Animals were killed by decapita
tion and their brains removed for analysis.
FIG. 1A is a graph of the percent alkaline protease in
young (three to four month old) gerbils, old (twelve to

puri?ed and the carbonyl content of that enzyme is evalu
ated, there is a marked increase in the level of oxidized
50

istration of PBN in young gerbils had no e?‘ect on glutamine

synthetase activity, providing further evidence that the level

?fteen month old retired breeder) gerbils, old gerbils admin
istered 0.1 ml saline twice daily (b.i.d.), and old gerbils
administered 10 mg PBN/kg body weight b.i.d. for fourteen

of carbonyl is associated with normal function and chronic
administration of PBN has no effect on either the level of
carbonyl or on the marker enzyme activity. In contrast to the

days.
The results demonstrate that PBN is effective in restoring
alkaline protease levels in old animals to those levels present
in young animals.
FIG. 2A is a graph of the changes in protein oxidation
from brains of young and senescent gerbils, plotting nmol
protein carbonyl/mg protein versus days of treatment with

young gerbils, old gerbils given daily injections of PBN
60

three, seven and fourteen days and protein carbonyl levels
determined.

show a time related increase in glutamine synthetase activity
that parallels the reduction in protein carbonyl content,
indicating that the reduction in oxidized protein burden of
cells is associated with a recovery of the enzymatic activity
to the normal level seen in young adult gerbils.
It is important to note that there is no increase in enzy

PBN. The gerbils were given twice daily injections of 32
mg/kg PBN for fourteen days. Animals were killed at one,

protein in the presence of lowered glutamine synthetase
activity. As also demonstrated in FIG. 2B, repeated admin

matic activity above that seen in young adult gerbils. Thus
65

the treatment with PBN reverses the effect of aging on

enzymatic activity but does not result in an activation of
enzyme activity that exceeds the normal values.

5,578,617
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EXAMPLE 2

does not require any food reinforcement or any other reward
associated with the test. Naive animals are placed into the

Determination of Residual Eifect of PBN on

radial arm maze, are‘tested once and these di?ferences are
reliable on retest.

Reduction of Brain Enzyme Levels

As shown in FIGS. 3A, 3B, and 3C, as compared with
FIGS. 4A, 4B, and 4C, administration of 10 mg PBN/kg is
as effective as administration of 32 mg PBn/kg body weight

5

skilled in the art from the foregoing detailed description.

in restoring young enzyme levels. The appropriate dosages

Such modi?cations and variations are intended to come
within the scope of the appended claims.
We claim:
1. A method of improving short term memory in a patient

and full range of effective dosages for other species of
animals can be determined using a similar methodology.

The time related changes in protein oxidation and enzyme

activity following termination of twice daily dosing with

suffering from short term memory loss comprising admin

either 10 mg PBN/kg (FIGS. 3A, B, and C) or 32 mg
PBN/kg (FIGS. 4A, B, and C) are also shown by these
?gures. The results demonstrate that the effect of the PBN is

istering to said patient an effective amount of a composition

capable of treating said short term memory loss and improv
ing short term memory, said composition having as the
active agent a compound selected from the group consisting

unaltered one to three days after termination of treatment

twice daily with the PBN, although the PBN itself has a
half-life of three hours. At seven days, the enzyme levels are

altered by approximately 50%. At fourteen days, the oxi

20

dized enzymes have returned to approximately their pre
treatment levels.

Modi?cations and variations of the method and compo
sition for the treatment of aging will be obvious to those

of 5,5-dimethyl pyrroline N-oxide (DMPO); ot-(4-pyridyl
1-oxide)-N-tert-butylnitrone (POBN); and derivatives
thereof selected from the group consisting of hydroxy
POBNs and DMPOs, POBN and DMPO esters, acetoxy
POBNs and DMPOs, alkyl POBNs and DMPOs, alkoxy

.

EXAMPLE 3

POBNs and DMPOs and phenyl POBNs and DMPOs hav
25

Demonstration of Correlation Between Effect of
PBN on Brain Enzymes and Memory

ing spin trapping activity in vivo in tissue; and
a pharmaceutically acceptable carrier therefor.
2. The method of claim 1 wherein the compound is
provided in a dosage of between 1 and 300 mg/kg body

FIG. 5 demonstrates that there is a functional counterpart
to such treatment. Young and old gerbils were tested in a
radial arm maze test for spacial and short term memory.

weight.
3. The method of claim 2 wherein the compound is
provided in a dosage of between 1 and 10 mg/kg body

Animals were placed in the central hub of a eight armed
radial maze and given access to explore all eight arms of the

weight.

radial arm maze. When the animal completed the test of
4. The method of claim 1 wherein the active agent is
exploring each of the eight arms, the animal was removed 35 5,5-dimethyl pyrroline N-oxide.
from the maze. The number of times that the animals
5. The method of claim 1 wherein the active agent has the
reentered arms that had been previously entered was counted
formula:
as an error. Under ideal conditions animals will enter each

one of the eight arms but not reenter any of the arms. In

“7Q

many cases young adult gerbils (young) entered each of the
arms without reentering any of the arms. The time required
to enter all eight arms was also recorded but did not appear

to determine the e?‘iciency of the short term memory task. As
can be seen in FIG. 5, young gerbils made an average of 2.83
errors during the test session. In contrast, old gerbils made 45
an average of 6.82 errors, which is a highly signi?cant
difference between the two groups.

Young adult gerbils exposed to a period of transient

B l
0

wherein A and B are independently CH3, CH2OH,
CH2OW, or
(OWL.

ischernia, which is also an oxidizing process, make a sub
stantial number of errors with an average value of 15 errors

in such a test session. During the post ischernic period, there
is a marked build up of carbonyl protein and reduction in
glutamine synthetase activity similar to that which is seen in

aging.
Treatment of gerbils for seven days results in a marked
alteration in the number of errors seen with old gerbils.

55

wherein W is

Young gerbils given PBN for seven days were not signi?
cantly different from control gerbils whereas the old gerbils
given PBN for seven days showed a marked reduction in the

errors seen in a short term spacial memory task, the radial
arm maze. It should be noted that the radial arm maze test

0

0

o

0

||

II

II

II

-C——CH3,NI—I—C—Z—, [—C~—CH3,] —C—0Z,

number of errors and returned to the range of performance
seen with control young gerbils. Thus, there is a functional
counterpart to the biochemical changes that are seen in that

reduction in protein carbonyl and the increase in glutarnine
synthetase activity following chronic PBN treatment. This
functional counterpart is demonstrated by the number of

n is an integer from 1 to 5

or Z; and

Z is a C1 to CS straight or branched alkyl group.
6. The method of claim 1 wherein the active agent is
65

0t-(4-pyridyl l -oxide)-N-tert~butylnitrone.
7. The method of claim 1 wherein the active agent has the
formula:

5,578,617
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(a) at least one compound of the formula:

AQ
B

0%2

062

wherein A and B are independently CH3, CHZOH,
CHZOW, or

wherein
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or
OW

n is an integer from 1 to 5
wherein W is
20

25

Z is a C1 to C5 straight or branched alkyl group;
(b) at least one compound of the formula

or Z; and

S is H, (OR),1, wherein R is H,

0

i
Y
35

(I)

wherein Y is as de?ned above,

i

It is a whole number from 1 to 4, or

wherein
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl or

and

Z is a C1 to CS straight or branched alkyl group.
8. The method of claim 1 wherein the active agent is
provided in combination with a pharmaceutical carrier

OW

selected from the group consisting of mierospheres, lipo
somes, immobilizing substrates, polymeric matrices and

buifering agents.
9. The method of claim 1 wherein the short term memory
loss is associated with ischemia.
10. The method of claim 1 wherein the short term memory
loss is associated with progressive neuronal loss.
11. The method of claim 1 wherein the progressive
neuronal loss is due to Parkinson's disease.
12. The method of claim 1 wherein the progressive
neuronal loss is due to senile dementia.
13. The method of claim 1 wherein the progressive
neuronal loss is due to Alzheimer’s disease.
14. A method for improving short term memory in a

wherein W is
0

o

0

II

II

II

NH——C—Z—, —C—Cl-l3, —C—OZ,
55

or Z; and

S is H, (OR),,, wherein R is H,
0

[I
60

patient suiTering from short term memory loss comprising
administering to said patient an effective amount of a

compound selected from the group consisting of:

wherein Y is as de?ned above,

0
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liposomes, immobilizing substrates, polymeric matrices,

n is a whole number from 1 to 4, or

and buffering agents.

0

17. A method according to claim 14 wherein said com
pound is administered in a dosage of from 1 to 300 mg/kg

ll
—NH—C—Z;

body weight.
18. A method according to claim 14 wherein said com

pound is administered in a dosage of from 1 to 10 mg/kg

and

body weight.

Z is a C1 to C5 straight or branched alkyl group;
(c) at least one other 5,5-dimethyl pyrroline N-oxide
(DMPO) derivative selected from the group consisting

19. The method of claim 14 wherein the short term
memory loss is associated with ischemia.
20. The method of claim 14 wherein the short term

of hydroxy DMPOs, DMPO esters, acetoxy DMPOs,
alkyl DMPOs, alkoxy DMPOs and phenyl DMPOs
having spin trapping activity in vivo in tissue; and

memory loss is associated with progressive neuronal loss.
21. The method of claim 20 wherein the progressive
neuronal loss is due to Parkinson’s disease.

(d) at least one other alpha-(4-pyridyl 1-oxide)-N-tert
butylnitrone (POBN) derivative selected from the

22. The method of claim 20 wherein the progressive
neuronal loss is due to senile dementia.

group consisting of hydroxy POBNs, POBN esters,

acetoxy POBNs, alkyl POBNs, alkoxy POBNs and
phenyl POBNs having spin trapping activity in vivo in
tissue,

23. The method of claim 20 wherein the progressive
neuronal loss is due to Alzheimer’s disease.
24. The method of claim 14 wherein Y is tert-butyl.
25. The method according to claim 1 wherein said com

optionally in association with a pharmaceutically acceptable
carrier.
15. A method according to claim 14 wherein said com

pound is provided in combination with a pharmaceutical
carrier.
16. A method according to claim 14 wherein said com

pound is provided in combination with a pharmaceutical
carrier selected from the group consisting of microspheres,

pound is provided in combination with a pharmaceutical
carrierselected from the group consisting of microspheres,
25

liposomes, immobilizing substrates, polymeric matrices,
and bu?ering agents.

